• Return to Headlines

Investors look to Lighten Up on Shares of Biocryst Pharm, Shares Down 50.6% (BCRX)

By Shiri Gupta

Biocryst Pharm (NASDAQ:BCRX) is one of today's worst performing low-priced stocks, down 50.6% to $3.66 on 9.9x average daily volume. Biocryst Pharm has traded 9.4 million shares thus far today, vs. average volume of 953,000 shares per day. The stock has underperformed the Dow (-50.6% to the Dow's 0.6%) and underperformed the S&P 500 (-50.6% to the S&P's 0.7%) during today's trading.

Biocryst Pharm (NASDAQ:BCRX) has potential upside of 135.0% based on a current price of $3.66 and analysts' consensus price target of $8.60. The stock should run into initial resistance at its 200-day moving average (MA) of $7.93 and subsequent resistance at its 50-day MA of $8.01.

In the past 52 weeks, Biocryst Pharm share prices have been bracketed by a current low of $3.66 and a high of $9.95 and are now at $3.66. In the last five trading sessions, the 50-day moving average (MA) has fallen 0.4% while the 200-day MA has risen 0.3%.

BioCryst Pharmaceuticals, Inc. designs, optimizes, and develops small-molecule novel pharmaceuticals that block key enzymes involved in infectious diseases, inflammatory diseases, and cancer. The Company has late-stage compounds in development and continues to discover additional compounds and to progress them to meet the unmet medical needs of patients and physicians.

SmarTrend is tracking the current trend status for Biocryst Pharm and will alert subscribers who have BCRX in their portfolio or watchlist when shares have changed trend direction.

Keywords: penny stocks biocryst pharm

Ticker(s): BCRX